Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry

被引:171
作者
McMillan, K
Adler, M
Auld, DS
Baldwin, JJ
Blasko, E
Browne, LJ
Chelsky, D
Davey, D
Dolle, RE
Eagen, KA
Erickson, S
Feldman, RI
Glaser, CB
Mallari, C
Morrissey, MM
Ohlmeyer, MHJ
Pan, CH
Parkinson, JF
Phillips, GB
Polokoff, MA
Sigal, NH
Vergona, R
Whitlow, M
Young, TA
Devlin, JJ
机构
[1] Pharmacopeia Inc, Princeton, NJ 08512 USA
[2] Berlex Biosci, Discovery Res, Richmond, CA 94804 USA
[3] Berlex Biosci, Gene Therapy & Genom, Richmond, CA 94804 USA
[4] Berlex Biosci, Canc Res, Richmond, CA 94804 USA
[5] Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA
关键词
D O I
10.1073/pnas.97.4.1506
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Potent and selective inhibitors of inducible nitric oxide synthase (iNOS) (EC 1.14.13.39) were identified in an encoded combinatorial chemical library that blocked human iNOS dimerization, and thereby NO production. In a cell-based iNOS assay (A-172 astrocytoma cells) the inhibitors had low-nanomolar IC50 values and thus were >1,000-fold more potent than the substrate-based direct iNOS inhibitors 1400W and N-methyl-L-arginine. Biochemical studies confirmed that inhibitors caused accumulation of iNOS monomers in mouse macrophage RAW 264.7 cells. High affinity (K-d approximate to 3 nM) of inhibitors for isolated iNOS monomers was confirmed by using a radioligand binding assay. Inhibitors were >1,000-fold selective for iNOS versus endothelial NOS dimerization in a cell-based assay. The crystal structure of inhibitor bound to the monomeric iNOS oxygenase domain revealed inhibitor-heme coordination and substantial perturbation of the substrate binding site and the dimerization interface, indicating that this small molecule acts by allosterically disrupting protein-protein interactions at the dimer interface. These results provide a mechanism-based approach to highly selective iNOS inhibition. Inhibitors were active in vivo, with ED50 values of <2 mg/kg in a rat model of endotoxin-induced systemic iNOs induction. Thus, this class of dimerization inhibitors has broad therapeutic potential in iNOS-mediated pathologies.
引用
收藏
页码:1506 / 1511
页数:6
相关论文
共 38 条
  • [1] Intracellular assembly of inducible NO synthase is limited by nitric oxide-mediated changes in heme insertion and availability
    Albakri, QA
    Stuehr, DJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (10) : 5414 - 5421
  • [2] Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018
  • [3] Beal MF, 1998, ANN NEUROL, V44, pS110
  • [4] ISOLATION OF NITRIC-OXIDE SYNTHETASE, A CALMODULIN-REQUIRING ENZYME
    BREDT, DS
    SNYDER, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (02) : 682 - 685
  • [5] NITRIC-OXIDE - A PHYSIOLOGICAL MESSENGER MOLECULE
    BREDT, DS
    SNYDER, SH
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1994, 63 : 175 - 195
  • [6] CLONED AND EXPRESSED NITRIC-OXIDE SYNTHASE STRUCTURALLY RESEMBLES CYTOCHROME-P-450 REDUCTASE
    BREDT, DS
    HWANG, PM
    GLATT, CE
    LOWENSTEIN, C
    REED, RR
    SNYDER, SH
    [J]. NATURE, 1991, 351 (6329) : 714 - 718
  • [7] Active-site structure analysis of recombinant human inducible nitric oxide synthase using imidazole
    Chabin, RM
    McCauley, E
    Calaycay, JR
    Kelly, TM
    MacNaul, KL
    Wolfe, GC
    Hutchinson, NI
    Madhusudanaraju, S
    Schmidt, JA
    Kozarich, JW
    Wong, KK
    [J]. BIOCHEMISTRY, 1996, 35 (29) : 9567 - 9575
  • [8] The structure of nitric oxide synthase oxygenase domain and inhibitor complexes
    Crane, BR
    Arvai, AS
    Gachhui, R
    Wu, CQ
    Ghosh, DK
    Getzoff, ED
    Stuehr, DJ
    Tainer, JA
    [J]. SCIENCE, 1997, 278 (5337) : 425 - 431
  • [9] Structure of nitric oxide synthase oxygenase dimer with pterin and substrate
    Crane, BR
    Arvai, AS
    Ghosh, DK
    Wu, CQ
    Getzoff, ED
    Stuehr, DJ
    Tainer, JA
    [J]. SCIENCE, 1998, 279 (5359) : 2121 - 2126
  • [10] Dawson V L, 1995, Adv Pharmacol, V34, P323